Pharming (PHAR) Liabilities and Shareholders Equity (2019 - 2025)

Pharming's Liabilities and Shareholders Equity history spans 7 years, with the latest figure at $500.0 million for Q4 2025.

  • Quarterly results put Liabilities and Shareholders Equity at $500.0 million for Q4 2025, up 25.0% from a year ago — trailing twelve months through Dec 2025 was $1.8 billion (up 6.09% YoY), and the annual figure for FY2025 was $500.0 million, up 25.0%.
  • Liabilities and Shareholders Equity for Q4 2025 was $500.0 million at Pharming, up from $400.0 million in the prior quarter.
  • In the past five years, Liabilities and Shareholders Equity ranged from a high of $500.0 million in Q4 2025 to a low of $397.3 million in Q4 2021.
  • The 5-year median for Liabilities and Shareholders Equity is $425.8 million (2022), against an average of $437.2 million.
  • The sharpest move saw Liabilities and Shareholders Equity fell 13.58% in 2024, then rose 25.0% in 2025.
  • Year by year, Liabilities and Shareholders Equity stood at $397.3 million in 2021, then grew by 7.17% to $425.8 million in 2022, then increased by 8.7% to $462.9 million in 2023, then fell by 13.58% to $400.0 million in 2024, then increased by 25.0% to $500.0 million in 2025.
  • According to Business Quant data, Liabilities and Shareholders Equity over the past three periods came in at $500.0 million, $400.0 million, and $462.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.